APREA THERAPEUTICS, INC.

(APRE)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics, Inc. Announces Updated Results from Its Phase 2 Trial Evaluating Eprenetapopt with Azacitidine for Post-Transplant Maintenance Therapy in Patients with TP53 mutant MDS and AML

12/13/2021 | 08:00am EDT

Aprea Therapeutics, Inc. announced updated results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML at the 2021 ASH Annual Meeting. In 33 patients enrolled in the trial, the relapse free survival (RFS) at 1 year post-transplant was 60% and the median RFS was 12.5 months. The overall survival (OS) at 1 year post-transplant was 79%, with a median OS of 20.6 months. Published studies evaluating post-transplant outcomes in TP53 mutant MDS and AML patients have reported a 1-year post-transplant RFS of ~30% and a median OS of ~5-8 months. In addition, the post- transplant regimen of eprenetapopt and azacitidine was well tolerated among patients in the clinical trial. Given the encouraging data, the Company intends to explore opportunities to conduct future randomized clinical trials to further assess safety and efficacy of this combination in the post-transplant maintenance setting.


© S&P Capital IQ 2021
All news about APREA THERAPEUTICS, INC.
05/17APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/17APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
CI
05/16APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/16TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
CI
05/16APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
05/16Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
GL
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Composite Index
CI
05/16ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
CI
03/16HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral..
MT
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 15,2 M 15,2 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 90,0%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-77.04%15
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567